Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging studyResearch in context

Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging studyResearch in context

Summary: Background: Janus kinase (JAK) inhibition is a promising approach for treating vitiligo. We aimed to assess the efficacy and safety of upadacitinib, an oral selective JAK inhibitor, in adults with non-segmental vitiligo. Methods: This was a phase 2, multicentre, randomised, double-blind, p...

Full description

Bibliographic Details
Main Authors: Thierry Passeron, Khaled Ezzedine, Iltefat Hamzavi, Nanja van Geel, Bethanee J. Schlosser, Xiaoqiang Wu, Xiaohong Huang, Ahmed M. Soliman, David Rosmarin, John E. Harris, Heidi S. Camp, Amit G. Pandya
Format: Article
Language:English
Published: Elsevier 2024-07-01
Series:EClinicalMedicine
Subjects:
Clinical trial
Phase 3
Janus kinase inhibitors
Randomised controlled trial
Upadacitinib
Vitiligo
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024002347

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024002347

Similar Items